Y

et another showdown over the high cost of medicines is taking place in Ireland, where the government and the maker of a cystic fibrosis treatment are locked in a battle that has enraged and worried patients.

The struggle is over Orkambi, a drug sold by Vertex Pharmaeuticals that has a price tag of about $170,000 a year. But Ireland’s National Centre for Pharmacoeconomics determined the medicine would be cost effective only if it were priced at about $32,000 per patient and did not recommend reimbursement. Consequently, Ireland’s Health Service Executive has so far refrained from providing coverage.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.